| human | Q5 |
| P496 | ORCID iD | 0000-0003-0401-4664 |
| P734 | family name | Van Assche | Q7913127 |
| Van Assche | Q7913127 | ||
| Van Assche | Q7913127 | ||
| P735 | given name | Gert | Q5553169 |
| Gert | Q5553169 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q46605155 | (Auto)antibodies in inflammatory bowel diseases |
| Q38962353 | 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management |
| Q57265315 | 5-Aminosalicylate is Not Protective From Neoplasia in Ulcerative Colitis |
| Q53038984 | A Simplified Geboes Score for Ulcerative Colitis. |
| Q44902578 | A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis |
| Q44833501 | A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis |
| Q38749257 | A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases |
| Q38005811 | Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients |
| Q37290464 | Adalimumab in Crohn's disease |
| Q34156631 | Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial |
| Q41594732 | Aeromonas species: an opportunistic enteropathogen in patients with inflammatory bowel diseases? A single center cohort study |
| Q34143725 | Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis |
| Q50708114 | Anti-Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases. |
| Q34145454 | Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease |
| Q48020945 | Anxiety is associated with impaired tolerance of colonoscopy preparation in inflammatory bowel disease and controls |
| Q34108445 | Assessment of the microbiota in microdissected tissues of Crohn's disease patients |
| Q47771380 | Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study |
| Q38355452 | Balloon dilatation of ileo-colonic anastomosis in Crohn's disease |
| Q49604701 | Balloon dilation of intrinsic small bowel strictures, still doubts about its efficacy? |
| Q37403184 | Biological therapies for inflammatory bowel diseases |
| Q38798137 | Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease |
| Q47808994 | Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study |
| Q35912315 | C-reactive protein as a marker for inflammatory bowel disease |
| Q47299575 | CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue |
| Q37153407 | Cancer risk in immune-mediated inflammatory diseases (IMID). |
| Q40336783 | Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model |
| Q50165756 | Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial |
| Q53122367 | Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. |
| Q38014622 | Classification of inflammatory bowel disease: the old and the new. |
| Q48222947 | Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial |
| Q43413021 | Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease |
| Q57457834 | Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach |
| Q57265320 | Correlation Between the Endoscopic and Histologic Score in Assessing the Activity of Ulcerative Colitis |
| Q57265353 | Corrigendum to “Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis” [J Crohn's and Colitis 4 (2010) 683–6. Epub 2010 Jul 14] |
| Q57265329 | Crohn's Disease |
| Q57265413 | Dealing With Infusion Reactions |
| Q46480302 | Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: A role for serological markers and microbial pattern recognition receptor genes |
| Q35828147 | Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease |
| Q39227272 | Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. |
| Q35954116 | Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease |
| Q39025057 | Effects of Education and Information on Vaccination Behavior in Patients with Inflammatory Bowel Disease |
| Q60949690 | Effects of Epithelial IL-13Rα2 Expression in Inflammatory Bowel Disease |
| Q53341945 | Effects of T cell-induced colonic inflammation on epithelial barrier function. |
| Q44445378 | Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease |
| Q50935666 | Effects of introduction of an inflammatory bowel disease nurse position on the quality of delivered care. |
| Q34610304 | Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series |
| Q36478109 | Emerging biological treatments in inflammatory bowel diseases |
| Q38296805 | Endoscopic and medical management of fibrostenotic Crohn's disease |
| Q53819602 | Endoscopic management of Crohn's strictures. |
| Q36710815 | Endoscopic therapy of strictures in Crohn's disease |
| Q57265390 | Endoscopy in Inflammatory Bowel Diseases |
| Q48278013 | Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease? |
| Q48265538 | Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease |
| Q50232304 | Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial |
| Q46171162 | Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study |
| Q42595283 | Fecal biomarkers for the diagnosis and management of inflammatory bowel disease |
| Q34255362 | Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease |
| Q36665623 | Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies |
| Q43416020 | Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's disease |
| Q54577917 | Genetic association and functional role of Crohn disease risk alleles involved in microbial sensing, autophagy, and endoplasmic reticulum (ER) stress. |
| Q57265337 | Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients |
| Q34710712 | Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases |
| Q40114343 | Identifying predictors of low adherence in patients with inflammatory bowel disease |
| Q51752137 | IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. |
| Q45985778 | Immunogenicity to infliximab is associated with HLA-DRB1. |
| Q37471289 | Immunosuppression in inflammatory bowel disease: traditional, biological or both? |
| Q38976595 | Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis |
| Q40323292 | Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis |
| Q40591530 | Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment |
| Q57265392 | Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease |
| Q37811756 | Inflammatory bowel disease and colitis: new concepts from the bench and the clinic |
| Q40197473 | Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis |
| Q57265401 | Infliximab Therapy |
| Q48739378 | Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study |
| Q40422633 | Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model |
| Q37616675 | Infliximab therapy for patients with inflammatory bowel disease: 10 years on. |
| Q34449876 | Infliximab: the evidence for its place in therapy in ulcerative colitis. |
| Q57265459 | Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease |
| Q33766675 | Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease |
| Q34784772 | Integrated miRNA and mRNA expression profiling in inflamed colon of patients with ulcerative colitis |
| Q50934354 | Interleukin-15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab. |
| Q44935336 | Intersphincteric proctectomy with end-colostomy for anorectal Crohn's disease results in early and severe proximal colonic recurrence |
| Q57265419 | Intravenous iron therapy restores functional iron deficiency induced by infliximab |
| Q57265363 | Long-Term Monitoring of Infliximab Therapy for Perianal Fistulizing Crohn's Disease by Using Magnetic Resonance Imaging |
| Q53993145 | Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. |
| Q49579231 | Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease |
| Q57265403 | Long-term outcome after infliximab for refractory ulcerative colitis |
| Q41723687 | Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission |
| Q43798421 | Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis |
| Q40038096 | Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease |
| Q64261195 | Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease |
| Q57265405 | Management of loss of response to anti-TNF drugs: Change the dose or change the drug? |
| Q35792335 | Medical management of postoperative recurrence in Crohn's disease |
| Q38015962 | Medical therapy and mucosal healing |
| Q35731494 | Medical therapy for Crohn's disease strictures |
| Q36148164 | Medical treatment of inflammatory bowel diseases. |
| Q46210756 | Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-based vs Trough Concentration-based Dosing of Infliximab |
| Q30945619 | Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment |
| Q54387452 | Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. |
| Q36763425 | Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? |
| Q51739537 | Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. |
| Q45181649 | Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease |
| Q45773011 | Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis |
| Q22242048 | New serological markers in inflammatory bowel disease are associated with complicated disease behaviour |
| Q52647462 | New treatment options for inflammatory bowel diseases. |
| Q57035476 | No Change in Determining Crohn's Disease Recurrence or Need for Endoscopic or Surgical Intervention With Modification of Rutgeerts' Scoring System |
| Q35787448 | Optimizing anti-TNF treatment in inflammatory bowel disease |
| Q37630743 | Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease). |
| Q42066696 | Optimizing biologic therapy for treatment of inflammatory bowel disease |
| Q37324635 | Optimizing treatment of inflammatory bowel diseases with biologic agents |
| Q34410821 | Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial |
| Q50873898 | Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. |
| Q47837061 | Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy |
| Q47229176 | Outcome of restorative proctocolectomy with ileo-anal pouch for ulcerative colitis: effect of changes in clinical practice |
| Q41990775 | Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy |
| Q36007709 | Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease |
| Q51647910 | Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis. |
| Q57265381 | Postinfectious Irritable Bowel Syndrome: A Genetic Link Identified? |
| Q38835478 | Practical Approaches to "Top-Down" Therapies for Crohn's Disease |
| Q37521805 | Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases |
| Q51771485 | Predictors of early response to infliximab in patients with ulcerative colitis. |
| Q36025017 | Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD |
| Q57265346 | Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing |
| Q28255557 | Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease |
| Q42324569 | Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation |
| Q26852581 | Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus |
| Q39811035 | Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis |
| Q57265395 | Reply to Dr. Caprilli et al.'s letter |
| Q43964295 | Reply to Drs. Silva and Santana's letter |
| Q57265384 | Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects |
| Q53366826 | Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3- Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor Therapy. |
| Q57265426 | Role of biomarkers in the diagnosis of inflammatory bowel disease |
| Q40884136 | Role of genetics in prediction of disease course and response to therapy |
| Q36500011 | Safety issues with biological therapies for inflammatory bowel disease |
| Q48009777 | Sarcoidosis-Like Lesions: Another Paradoxical Reaction to Anti-TNF Therapy? |
| Q38049777 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis |
| Q38049776 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management |
| Q38049779 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations |
| Q50986872 | Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease. |
| Q57265385 | Serum S100A12 as a new marker for inflammatory bowel disease and its relationship with disease activity |
| Q37405694 | Serum sickness, encephalitis and other complications of anti-cytokine therapy |
| Q43977750 | Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC. |
| Q51600247 | Strong Upregulation of AIM2 and IFI16 Inflammasomes in the Mucosa of Patients with Active Inflammatory Bowel Disease. |
| Q57265349 | Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial |
| Q38890501 | Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease |
| Q38160905 | Targeting TNF-α for the treatment of inflammatory bowel disease |
| Q37918330 | The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety |
| Q51012059 | The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. |
| Q36217509 | The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile |
| Q41978311 | The optimization of immunosuppressive and biologic cotherapies in inflammatory bowel disease. |
| Q36331229 | The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases |
| Q44347748 | The role of aminosalicylates in the treatment of ulcerative colitis |
| Q54583401 | The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. |
| Q37814539 | The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis |
| Q34152778 | The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations |
| Q38164751 | The use of fecal calprotectin and lactoferrin in patients with IBD. Review |
| Q38254878 | The use of prognostic factors in inflammatory bowel diseases |
| Q37948705 | Therapeutic drug monitoring of biologics for inflammatory bowel disease |
| Q57265411 | Therapy of Metronidazole With Azathioprine to Prevent Postoperative Recurrence of Crohn's Disease: A Controlled Randomized Trial |
| Q54534519 | Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease. |
| Q27008246 | Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases |
| Q37276958 | Treatment of severe steroid refractory ulcerative colitis |
| Q47790438 | Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study |
| Q42238439 | Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening |
| Q30657855 | Unique gene expression and MR T2 relaxometry patterns define chronic murine dextran sodium sulphate colitis as a model for connective tissue changes in human Crohn's disease |
| Q34389541 | Vaccination and infection prevention in inflammatory bowel disease |
| Q37170458 | Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature |
| Q52884617 | Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis. |
| Q39120032 | Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy |
| Q34365566 | Vedolizumab as induction and maintenance therapy for ulcerative colitis |
| Q57453522 | Vedolizumab in refractory microscopic colitis: an international case series |
| Q30981424 | Visualization of delayed release of compounds from pH-sensitive capsules in vitro and in vivo in a hamster model |
| Q46623924 | Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial |
Search more.